Holen Sie sich die Stockscreener-App
8.27
0.24%
-0.02
Handel nachbörslich:
8.27
Schlusskurs vom Vortag:
$8.29
Offen:
$8.27
24-Stunden-Volumen:
1.58M
Relative Volume:
0.49
Marktkapitalisierung:
$1.74B
Einnahmen:
$557.51M
Nettoeinkommen (Verlust:
$-35.71M
KGV:
-45.94
EPS:
-0.18
Netto-Cashflow:
$15.50M
1W Leistung:
-2.36%
1M Leistung:
-5.27%
6M Leistung:
-0.48%
1J Leistung:
-0.12%
1-Tages-Spanne:
$8.19
$8.36
1-Wochen-Bereich:
$8.02
$8.49
52-Wochen-Spanne:
$6.015
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Firmenname
Biocryst Pharmaceuticals Inc
Sektor
Telefon
919-859-1302
Adresse
4505 EMPEROR BOULEVARD, DURHAM, NC
Vergleichen Sie BCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
8.27 | 1.74B | 557.51M | -35.71M | 15.50M | -0.18 |
|
ZTS
Zoetis Inc
|
153.20 | 67.75B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.29 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.84 | 43.70B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.48 | 21.51B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
380.47 | 18.31B | 2.99B | 1.21B | 1.13B | 25.06 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-02-25 | Eingeleitet | Wedbush | Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-02-22 | Hochstufung | Needham | Hold → Buy |
| 2022-11-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-08-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-05-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-08-08 | Fortgesetzt | JP Morgan | Overweight |
| 2018-07-17 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Eingeleitet | Seaport Global Securities | Neutral |
| 2018-01-02 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Eingeleitet | Barclays | Equal Weight |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Hochstufung | Jefferies | Hold → Buy |
| 2017-02-16 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-08-12 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | FBR Capital | Outperform |
| 2016-02-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Herabstufung | Needham | Buy → Hold |
Alle ansehen
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
Forecasting BioCryst Pharmaceuticals Inc. price range with options dataQuarterly Market Review & Expert Approved Momentum Trade Ideas - Newser
Understanding BioCryst Pharmaceuticals Inc.’s price movement2025 Institutional Moves & Verified Swing Trading Watchlists - Newser
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
71,400 RSUs and 36,700 Stock Options: BioCryst's Latest Employee Compensation Package Details - Stock Titan
Applying Elliott Wave Theory to BioCryst Pharmaceuticals Inc.Gap Up & Daily Profit Maximizing Trade Tips - Newser
What to do if you’re stuck in BioCryst Pharmaceuticals Inc.Earnings Risk Report & Expert Approved Trade Ideas - Newser
BioCryst Pharmaceuticals Inc. stock prediction for this weekEarnings Growth Summary & AI Driven Stock Movement Reports - Newser
How to read the order book for BioCryst Pharmaceuticals Inc.Trade Analysis Report & Daily Growth Stock Investment Tips - Newser
Is BioCryst Pharmaceuticals Inc. a defensive stockJuly 2025 Analyst Calls & Stock Portfolio Risk Management - khodrobank.com
Fibrodysplasia Ossificans Market to Experience Notable Growth in Forecast Span by 2032, DelveInsight Predicts | Ipsen, Regeneron Pharma, Biocryst - Barchart.com
Will BioCryst Pharmaceuticals Inc. benefit from rising consumer demandMarket Performance Report & Risk Controlled Stock Pick Alerts - khodrobank.com
How to build a custom watchlist for BioCryst Pharmaceuticals Inc.July 2025 Decliners & Expert Verified Stock Movement Alerts - Newser
Will BioCryst Pharmaceuticals Inc. see short term momentumTrade Signal Summary & Long-Term Safe Investment Plans - Newser
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 Revenue Soars 49%, Hits Record $163.4 Million on ORLADEYO Surge - Yahoo Finance
Is BioCryst Pharmaceuticals Inc. affected by consumer sentiment2025 Macro Impact & Low Volatility Stock Recommendations - khodrobank.com
Custom watchlist performance reports with BioCryst Pharmaceuticals Inc.2025 Support & Resistance & Daily Risk Controlled Trade Plans - Newser
Is BioCryst Pharmaceuticals Inc. backed by strong institutional buyingOptions Play & Daily Stock Momentum Reports - khodrobank.com
Is BioCryst Pharmaceuticals Inc. forming bullish engulfing patternsJuly 2025 PreEarnings & Consistent Growth Stock Picks - khodrobank.com
Is BioCryst Pharmaceuticals Inc.’s growth already priced in2025 Market Sentiment & Stock Market Timing Techniques - khodrobank.com
Will BioCryst Pharmaceuticals Inc. outperform its industry peersCEO Change & Weekly High Potential Alerts - khodrobank.com
Is BioCryst Pharmaceuticals Inc. still worth holding after the dipMarket Activity Report & AI Driven Stock Reports - Newser
BioCryst Pharmaceuticals Inc. Inches Above Key Support — Safe to Hold getLinesFromResByArray error: size == 0 - kangso.co.kr
Is a relief rally coming for BioCryst Pharmaceuticals Inc. holdersInsider Selling & Real-Time Stock Movement Alerts - Newser
Published on: 2025-09-01 00:02:12 - Newser
What to do if you’re stuck in BioCryst Pharmaceuticals IncTrade Risk Summary & Long-Term Capital Growth Ideas - Newser
How to track smart money flows in BioCryst Pharmaceuticals Inc.2025 Market Outlook & Reliable Breakout Forecasts - Newser
Leading vs lagging indicators on BioCryst Pharmaceuticals Inc. performanceEarnings Recap Report & Daily Profit Focused Screening - Newser
Will BioCryst Pharmaceuticals Inc. stock benefit from AI tech trendsGDP Growth & Weekly Chart Analysis and Guides - Newser
Best data tools to analyze BioCryst Pharmaceuticals Inc. stock2025 Key Lessons & Step-by-Step Trade Execution Guides - Newser
Published on: 2025-08-31 13:57:41 - Newser
Chart based exit strategy for BioCryst Pharmaceuticals Inc.Market Risk Summary & Technical Confirmation Alerts - Newser
Published on: 2025-08-31 12:26:45 - Newser
Can technical indicators confirm BioCryst Pharmaceuticals Inc.’s reversal2025 Analyst Calls & Weekly Watchlist of Top Performers - Newser
Applying Elliott Wave Theory to BioCryst Pharmaceuticals IncJuly 2025 Patterns & Reliable Volume Spike Alerts - Newser
Is BioCryst Pharmaceuticals Inc. forming a bottoming baseJuly 2025 Reactions & Free High Accuracy Swing Entry Alerts - Newser
Is BioCryst Pharmaceuticals Inc. a candidate for recovery playMarket Movement Recap & Pattern Based Trade Signal System - Newser
Published on: 2025-09-02 01:35:10 - Newser
What MACD and RSI say about BioCryst Pharmaceuticals Inc.Weekly Market Outlook & Daily Profit Focused Screening - Newser
What momentum shifts mean for BioCryst Pharmaceuticals Inc.July 2025 Summary & Free Daily Entry Point Trade Alerts - Newser
Finanzdaten der Biocryst Pharmaceuticals Inc-Aktie (BCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biocryst Pharmaceuticals Inc-Aktie (BCRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| HEGGIE THERESA | Director |
Aug 13 '25 |
Sale |
8.51 |
70,000 |
595,868 |
65,352 |
3.60%
0.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):